HIV type 1 drug resistance patterns among patients failing first and second line antiretroviral therapy in Nairobi, Kenya

被引：10

作者：

Koigi P. ^{[1
]}

Ngayo M.O. ^{[2
]}

Khamadi S. ^{[3
]}

Ngugi C. ^{[4
]}

Nyamache A.K. ^{[3
,5
]}

机构：

[1] Department of Medical Laboratory Sciences, Kenyatta University, Nairobi

[2] Center for Microbiology Research, Kenya Medical Research Institute, Nairobi

[3] Centre for Virus Research, Kenya Medical Research Institute, Nairobi

[4] Department of Medical Microbiology, Jomo Kenyatta University of Agriculture and Technology, Nairobi

[5] Department of Microbiology, Kenyatta University, Nairobi

来源：

BMC Research Notes | / 7卷 / 1期

关键词：

Antiretroviral drug resistance; Resource-limited settings; Second-line therapy;

D O I：

10.1186/1756-0500-7-890

中图分类号：

学科分类号：

摘要：

Background: The ever-expanding rollout of antiretroviral therapy in poor resource settings without routine virological monitoring has been accompanied with development of drug resistance that has resulted in limited treatment success. Methods: A cross-sectional study with one time viral load was conducted during the period between 2012 and 2013 to determine treatment failure and drug resistance mutations among adults receiving first-line (44) (3TC-d4T/ AZT-NVP/EFV) and second-line (20) (3TC/AZT/LPV/r) in Nairobi, Kenya. HIV-1 pol-RT genotyping for drug resistance was performed using an in-house protocol. Results: A total of 64 patients were recruited (mean age 36.9 yrs.) during the period between 2012 and 2013 of the 44 adult patients failing first-line 24 (40.9%) had drug resistance mutations. Eight (8) patients had NRTI resistance mutations with NAMS M184V (54.2%) and K65R (8.4%) mutations being the highest followed by TAMs T215Y and K70R (12.5%). In addition, among patients failing second-line (20), six patients (30%) had NNRTI resistance; two patients on K103N and G190A mutations while V106A, Y184V, A98G, Y181C mutations per patient were also detected. However, for NRTI two patients had TAM T215Y. M184V mutation occurred in one patient. Conclusions: The study findings showed that HIV-1 drug resistance was significantly high in the study population. The detected accumulated resistance strains show that emergence of HIV drug resistance will continue to be a big challenge and should be given more attention as the scale up of treatment in the country continues. © 2014 Koigi et al.; licensee BioMed Central Ltd.

引用

共 24 条

[1]

Lihana R.W., Khamadi S.A., Lubano K., Mwangi J., Kinyua J.G., Okoth V.O., Lagat N.J., Okoth F.A., Songok E.M., Makokha E.P., Genetic characterization of HIV Type 1 among patients with suspected immune reconstitution inflammatory syndrome after initiation of antiretroviral therapy in Kenya, AIDS Res Hum Retroviruses, 26, 7, pp. 833-898, (2010)

[2]

Monleau M., Faihun F., Affolabi D., Angnihoun A., Boillot F., Anagonou S., Peeters M., Delaporte E., Antiretroviral drug resistance in HIV-1 infected patients receiving antiretroviral treatment in routine clinics in Cotonou, Benin, J AIDS HIV Res, 3, 6, pp. 114-120, (2011)

[3]

Nyamache A.K., Muigai W.T., Nganga Z., Khamadi S.A., HIV-1 genetic diversity and naturally occurring polymorphisms in HIV-1 Kenyan isolates: Implications for integrase inhibitors, AIDS Res Hum Retroviruses, 28, 8, pp. 933-936, (2012)

[4]

National AIDS and STI Control Programme (NASCOP), Kenya HIV Drug Resistance Country Report

[5]

National AIDS and STI Control Programme (NASCOP), Guidelines for Antiretroviral Therapy in Kenya, (2011)

[6]

WHO, WHO Global Strategy for the Surveillance and Monitoring of HIV Drug Resistance 2012 WHO, (2012)

[7]

Wallis C.L., Erasmus L., Varughese S., Ndiweni D., Stevens W.S., Emergence of drug resistance in HIV-1 subtype C infected children failing the South-African National Antiretroviral roll-out program, Pediatr Infect Dis J, 28, pp. 1123-1125, (2009)

[8]

Van Zyl G.U., Liu T.F., Claassen M., Engelbrecht S., Oliveira T., Preiser W., Wood N.T., Travers S., Shafer R.W., Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first-and second-line antiretroviral treatment regimens, PLoS One, 8, 6, (2013)

[9]

Gakhar H., Kamali A., Holodniy M., Health-related quality of life assessment after antiretroviral therapy: A review of the literature, Drugs, 73, 7, pp. 651-672, (2013)

[10]

Vidya M., Saravanan S., Uma S., Kumarasamy N., Sunil S.S., Kantor R., Katzenstein D., Ramratnam B., Mayer K.H., Suniti S., Balakrishnan P., Genotypic HIV type-1 drug resistance among patients with immunological failure to first-line antiretroviral therapy in south India, Antivir Ther, 14, 7, (2009)

← 1 2 3 →